Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 Novembro 2023 - 6:05PM
Business Wire
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced that on November 8, 2023, the Compensation
Committee of Guardant’s Board of Directors granted restricted stock
units (“RSUs”) representing 50,741 shares of its common stock to 43
new non-executive employees under the Guardant Health, Inc. 2023
Employment Inducement Incentive Award Plan (the “Inducement Plan”).
The RSUs were granted as inducements material to the employees
entering into employment with Guardant in accordance with Nasdaq
Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of
Guardant, or following a bona fide period of non-employment, as an
inducement material to such individuals’ entering into employment
with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).
One-third of the shares underlying the RSU award vest on an
annual basis on the anniversary of the vesting commencement date,
subject to each employee’s continued employment with Guardant as of
each such vesting date. The RSUs are subject to the terms and
conditions of the Inducement Plan and the terms and conditions of a
RSU award agreement covering the grant.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360 CDx,
Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI®
tests for advanced stage cancer patients, and Guardant Reveal™ for
early-stage cancer patients. The Guardant Health screening
portfolio, including the Shield™ test, aims to address the needs of
individuals eligible for cancer screening. For more information,
visit guardanthealth.com and follow the company on LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231115453262/en/
Investor Contact: investors@guardanthealth.com
Media Contact: Melissa Marasco press@guardanthealth.com
+1 650-647-3711
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024